Remove 2030 Remove FDA Remove Pharmaceutical Companies
article thumbnail

AI to revolutionise drug development by 2026

European Pharmaceutical Review

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months.

FDA 105
article thumbnail

Eli Lilly achieving significant gains in obesity results

Pharmaceutical Technology

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. A decision from the FDA is possible for later this year, with Lilly currently finalizing an application for fast-track approval.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene therapy: a radical pharmaceutical revolution

European Pharmaceutical Review

billion by 2030. The US Food and Drug Administration (FDA) requires a patient follow up period of at least 10-15 years. Internet] FDA. Available from: [link] The post Gene therapy: a radical pharmaceutical revolution appeared first on European Pharmaceutical Review. Internet] European Medicines Agency.

article thumbnail

‘Insulin for muscle’ and the AI platform behind it, with Hanadie Yousef

pharmaphorum

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

2nd Translational Digital Pathology & AI Summit

pharmaphorum

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

After rebuffing Biogen, Sage pairs off with Supernus

pharmaphorum

Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Pandemic Like Never Before – Continuous Manufacturing to the Rescue

Roots Analysis

However, the road for transition from the conventional batch to continuous manufacturing requires a shift in variety of parameters and is still quite unclear to many of the pharmaceutical companies. However, in 2030 as well, North America and Europe are likely to contribute an equal amount of share to the market.